Pharmaceutical design of antimitotic agents based on combretastatins

Current Pharmaceutical Design

Volumn 11, Issue 13, 2005, Pages 1655-1677

  Hsieh, H P ^a   Liou, J P ^a   Mahindroo, N ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Antimitotic agents; Antivascular; Aroylindoles; Benzophenones; Combretastatin A 4; Combretastatins; Drug design; Tubulin polymerization

Indexed keywords

A 105972; A 204197; A 259745; A 289099; A 289101; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AVE 8063; BPR 0L075; CHALCONE DERIVATIVE; CISPLATIN; COMBRETASTATIN; COMBRETASTATIN A1; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A2; COMBRETASTATIN A3; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; COMBRETASTATIN A5; COMBRETASTATIN B1; COMBRETASTATIN B1 PHOSPHATE; DOXORUBICIN; PHENSTATIN DERIVATIVE; RALOXIFENE; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; TUBULIN; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ATAXIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBRETUM; CYTOTOXICITY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DYSPNEA; FATIGUE; HUMAN; HYPERTENSION; HYPOTENSION; LYMPHOCYTOPENIA; MICROTUBULE ASSEMBLY; MOTOR NEUROPATHY; PAIN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STOMATITIS; SYNCOPE; VISUAL DISORDER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BIBENZYLS; CLINICAL TRIALS; DRUG DESIGN; HUMANS; STILBENES;

EID: 18744379774     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053764751     Document Type: Review

References (115)

1. Baguley BC. A brief history of cancer chemotherapy. In: Baguley BC, Karr DJ, Eds. Anticancer drug development. London, Academic Press: 2002; 1-11.
2. Newman JD, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep 2000; 17: 215-34.
3. Newman JD, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003; 66: 1022-37.
4. Lee KH. Current developments in the discovery and design of new drug candidates from plant natural product leads. J Nat Prod 2004; 67: 273-83.
5. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1: 222-31.
6. Blagosklonny MV. Mechanisms of action of cancer chemotherapeutic agents: Antimicrotubule agents. In: Alison M, Ed. The cancer handbook, Nature Publishing Group: 2004, 1323-32.
7. Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2001; 2: 82-7.
8. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy, Int J Cancer 2002; 99: 1-6.
9. Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 1987; 50:119-31.
10. Pettit GR, Singh SB, Schmidt JM, Niven ML, Hamel E, Lin CM. Isolation, structure, synthesis, and antimitotic properties of combretastatins B-3 and B-4 from Combretum caffrum. J Nat Prod 1988; 51: 517-27.
11. Nam NH. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr Med Chem 2003; 10: 1697-722.
12. Li Q, Sham HL. Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer. Expert Opin Ther Patents 2002; 12: 1663-1702.
13. Bibby MC. Combretastatin anticancer drugs. Drug Future 2002; 27: 475-80.
14. Adams J, Elliott PJ. New agents in cancer clinical trials. Oncogene 2000; 19: 6687-92.
15. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253-70.
16. Verdier-Pinard P, Lansiaux A, Bailly C. Combretastatin A4 phosphate. Bull Cancer 2001; 88: 235-9.
17. Randal J. Antiangiogenesis drugs target specific cancers, mechanisms. J Natl Cancer Inst 2000; 92: 520-2.
18. O'Brien C. Combretastatin A-4 vascular damage to tumours. Mol Med Today 1997; 3: 369.
19. Puduvalli VK, Sawaya R. Antiangiogenesis - therapeutic strategies and clinical implications for brain tumors. J Neurooncol 2000; 50: 189-200.
20. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 2002; 83: 21-38.
21. Woods JA, Hadfield JA, Pettit GR, Fox BW, McGown AT. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 1995; 71: 705-11.
22. Pettit GR, Singh SB. Isolation, structure, and synthesis of combretastatin A-2, A-3, and B-2. Can J Chem 1987; 65: 2390-6.
23. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989; 45:209-11.
24. Pettit GR, Singh SB, Boyd MR, Hamel E, Pettit RK, Schmidt JM, et al. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). J Med Chem 1995; 38: 1666-72.
25. Pettit GR, Singh SB, Niven ML, Schmidt JM. Cell growth inhibitory dihydrophenanthrene and phenanthrene constituents of the Affrican tree Combretum caffrum. Can J Chem 1988; 66: 406-13.
26. Singh SB, Petit GR. Isolation, structure, and synthesis of combretastatin C-1. J Org Chem 1989; 54: 4105-14.
27. Pettit GR, Singh SB, Niven ML. Antineoplastic agents. 160. Isolation and structure of combretastatin D-1: a cell growth inhibitory macrocyclic lactone from Combretum caffrum. J Am Chem Soc 1988; 110: 8539-40.
28. Singh SB, Pettit GR. Antineoplastic agents. 206. Structure of the cytostatic macrocyclic lactone combretastatin D-2. J Org Chem 1990; 55: 2797-2800.
29. McGown AT, Fox BW. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des 1989; 3:249-54.
30. Hamel E, Lin CM. Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin. Biochem Pharmacol 1983; 32: 3864-7.
31. Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR, et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 1988; 34: 200-8.
32. Lin CM, Ho HH, Pettit GR, Hamel E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989; 28: 6984-91.
33. Bedford SB, Quarterman CP, Rathbone DL, Slack JA, Griffin R J, Stevens MFG. Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4. Bioorg Med Chem Lett 1996; 6: 157-60.
34. Brown RT, Fox BW, Hadfield JA, McGown AT, Mayalarp SP, Pettit GR, et al. Synthesis of water-soluble sugar derivatives of combretastatin A-4. J Chem Soc Perkin Trans 1 1995: 577-81.
35. Hadimani MB, Hua J, Jonklaas MD, Kessler RJ, Sheng Y, Olivares A, et al. Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4. Bioorg Med Chem Lett 2003; 13: 1505-8.
36. Pettit GR, Temple C Jr, Narayanan VL, Varma R, Simpson MJ, Boyd MR, et al. Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 1995; 10: 299-309.
37. Pettit GR, Rhodes MR. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des 1998; 13: 183-91.
38. Pettit GR, Lippert JW 3rd. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des 2000; 15: 203-16.
39. Hill SA, Toze GM, Pettit GR, Chaplin DJ. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 2002; 22: 1453-8.
40. Kirwan IG, Loadman PM, Swaine DJ, Anthoney DA, Pettit GR, Lippert JW 3rd, et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 2004; 10: 1446-53.
41. Pettit GR, Minardi MD, Boyd MR, Pettit RK. Antineoplastic agents 463. Synthesis of combretastatin A-3 diphosphate prodrugs. Anticancer Drug Des 2000; 15: 397-403.
42. Lawrence NJ, Hepworth LA, Rennison D, McGown AT, Hadfield JA. Synthesis and anticancer activity of fluorinated analogues of combretastatin A-4. J Fluorine Chem 2003; 123: 101-8.
43. Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka T, Morinaga Y, Nihei Y, et al. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J Med Chem 1998; 41: 3022-32.
44. Pinney KG, Mejia MP, Villalobos VM, Rosenquist BE, Pettit GR, Verdier-Pinard P, et al. Synthesis and biological evaluation of aryl azide derivatives of combretastatin A-4 as molecular probes for tubulin. Bioorg Med Chem 2000; 8: 2417-25.
45. Ohsumi K, Hatanaka T, Nakagawa R, Fukuda Y, Morinaga Y, Suga Y, et al. Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins. Anticancer Drug Des 1999; 14: 539-48.
46. Nihei Y, Suga Y, Morinaga Y, Ohishi K, Okano A, Ohsumi K, et al. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 1999; 90: 1016-25.
47. Hori K, Saito S, Nihei Y, Suzuki M, Sato Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 1999; 90: 1026-38.
48. Hori K, Saito S, Sato Y, Kubota K. Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med Sci Monit 2001; 7: 26-33.
49. Hori K, Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 2003; 89: 1334-44.
50. Hori K, Saito S. Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVES062 (AC7700). Br J Cancer 2004; 90: 549-53.
51. Hori K, Saito S, Sato Y, Akita H, Kawaguchi T, Sugiyama K, et al. Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). Eur J Cancer 2003; 39: 1957-66.
52. Pettit GR, Anderson CR, Herald DL, Jung MK, Lee DJ, Hamel E, et al. Antineopastic agents. 487. Synthesis and biological evaluation of the antineoplastic agent 3, 4-methylenedioxy-5, 4′-dimethoxy-3′-amino-Z-stilbene and derived amino acid amides. J Med Chem 2003; 46: 525-31.
53. Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000; 20: 229-33.
54. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999; 19: 189-95.
55. Li L, Rojiani AM, Siemann DW. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol 2002; 41: 91-7.
56. Nelkin BD, Ball DW. Combretustatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 2001; 8:157-60.
57. Wildiers H, Ahmed B, Guetens G, De Boeck G, de Bruijn EA, Landuyt W, et al. Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. Eur J Cancer 2004; 40: 284-90.
58. Morinaga Y, Suga Y, Ehara S, Harada K, Nihei Y, Suzuki M. Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 2003; 94: 200-4.
59. Oxigene. Combretastatin A-4P clinical trials. http://www.oxigene.com/vascular/pipeline.asp 2004.
60. Dowlati A, Robertson K, Cooney M, Perros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62: 3408-16.
61. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003; 21: 2815-22.
62. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003; 21: 2823-30.
63. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003; 21:2831-42.
64. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21: 4428-38.
65. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, et al. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004; 10: 96-100.
66. Cushman M, Nagarathnam D, Gopal D, Chakraborti AK, Lin CM, Hamel E. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. J Med Chem 1991; 34: 2579-88.
67. Cushman M, Nagarathnam D, Gopal D, He HM, Lin CM, Hamel E. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3, 4, 5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. J Med Chem 1992; 35: 2293-306.
68. Pettit GR, Toki B, Herald DL, Verdier-Pinard P, Boyd MR, Hamel E, et al. Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J Med Chem 1998; 41: 1688-95.
69. Pettit GR, Lippert JW 3rd, Herald DL. A Pinacol rearrangement/oxidation synthetic route to hydroxyphenstatin. J Org Chem 2000; 65: 7438-44.
70. Pettit GR, Grealish MP, Herald DL, Boyd MR, Hamel E, Pettit RK. Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug. J Med Chem 2000; 43: 2731-7.
71. Pettit GR, Grealish MP, Jung MK, Hamel E, Pettit RK, Chapuis JC, et al. Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. J Med Chem 2002; 45: 2534-42.
72. Liou JP, Chang CW, Song JS, Yang YN, Yeh CF, Tseng HY, et al. Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. J Med Chem 2002; 45: 2556-62.
73. Liou JP, Chang JY, Chang CW, Chang CY, Mahindroo N, Kuo FM, et al. Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents. J Med Chem 2004; 47: 2897-905.
74. Hsieh HP, Liou JP, Lin YT, Mahindroo N, Chang JY, Yang YN, et al. Structure-activity and crystallographic analysis of benzophenone derivatives-the potential anticancer agents. Bioorg Med Chem Lett 2003; 13: 101-5.
75. Lawrence NJ, Rennison D, Woo M, McGown AT, Hadfield JA. Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg Med Chem Lett 2001; 11: 51-4.
76. Getahun Z, Jurd L, Chu PS, Lin CM, Hamel E. Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions. J Med Chem 1992; 35: 1058-67.
77. Hatanaka T, Fujita K, Ohsumi K, Nakagawa R, Fukuda Y, Nihei Y, et al. Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity. Bioorg Med Chem Lett 1998; 8: 3371-4.
78. Pettit GR, Rhodes MR, Herald DL, Chaplin DJ, Stratford MR, Hamel E, et al. Antineoplastic agents 393. Synthesis of the transisomer of combretastatin A-4 prodrug. Anticancer Drug Des 1998; 13: 981-93.
79. Pettit GR, Toki BE, Herald DL, Boyd MR, Hamel E, Pettit RK, et al. Antineoplastic agents. 410. Asymmetric hydroxylation of transcombretastatin A-4. J Med Chem 1999; 42: 1459-65.
80. Iwasaki S, Shirai R. Natural organic compounds that affect to microtubule functions: syntheses and structure-activity relationships of combretastatins, curacin A and their analogs as the colchicine-site ligands on tubulin. Yakugaku Zasshi 2000; 120: 875-89.
81. Medarde M, Ramos S, Caballero E, Lamamie de Clairac RP, Lopez JL, Gravalos DG, et al. Synthesis and antineoplastic activity of combretastatin analogues: Heterocombretastatins. Eur J Med Chem 1998; 33: 71-7.
82. Shirai R, Tokuda K, Koiso Y, Iwasaki S. Synthesis and anti-tubulin activity of aza-combretastatins. Bioorg Med Chem Lett 1994; 4: 699-704.
83. Gwaltney SL 2nd, Imade HM, Barr K J, Li Q, Gehrke L, Credo RB, et al. Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents. Bioorg Med Chem Lett 2001; 11: 871-4.
84. Shirai R, Takayama H, Nishikawa A, Koiso Y, Hashimoto Y. Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. Bioorg Med Chem Lett 1998; 8: 1997-2000.
85. Shirai R, Okabe T, Iwasaki S. Synthesis of conformationally restricted combretastatins. Heterocycles 1997; 46: 145-8.
86. Nam NH, Kim Y, You YJ, Hong DH, Kim HM, Ahn BZ. Synthesis and anti-tumor activity of novel combretastatins: combretocyclopentenones and related analogues. Bioorg Med Chem Lett 2002; 12: 1955-8.
87. Flynn BL, Flynn GP, Hamel E, Jung MK. The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4. Bioorg Med Chem Lett 2001; 11: 2341-3.
88. Kim Y, Nam NH, You YJ, Ahn BZ. Synthesis and cytotoxicity of 3, 4-diaryl-2(5H)-furanones. Bioorg Med Chem Lett 2002; 12: 719-22.
89. Nam NH, Kim Y, You YJ, Hong DH, Kim HM, Ahn BZ. Water soluble prodrugs of the antitumor agent 3-[(3-amino-4-methoxy)phenyl]-2-(3, 4, 5-trimethoxyphenyl)cyclopent-2-ene-1-one. Bioorg Med Chem 2003; 11: 1021-9.
90. Nam NH, Kim Y, You YJ, Hong DH, Kim HM, Ahn BZ. Combretoxazolones: synthesis, cytotoxicity and antitumor activity. Bioorg Med Chem Lett 2001; 11: 3073-6.
91. Ohsumi K, Hatanaka T, Fujita K, Nakagawa R, Fukuda Y, Nihei Y, et al. Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. Bioorg Med Chem Lett 1998; 8: 3153-8.
92. Wang L, Woods KW, Li Q, Barr KJ, McCroskey RW, Hannick SM, et al. Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem 2002; 45:1697-711.
93. Medarde M, Ramos AC, Caballero E, Pelaez-Lamamie de Clairac R, Lopez JL, Gravalos DG, et al. Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. Bioorg Med Chem Lett 1999; 9: 2303-8.
94. Flynn BL, Hamel E, Jung MK. One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. J Med Chem 2002; 45: 2670-3.
95. Pinney KG, Bounds AD, Dingeman KM, Mocharla VP, Pettit GR, Bai R, et al. A new anti-tubulin agent containing the benzo[b] thiophene ring system. Bioorg Med Chem Lett 1999; 9: 1081-86.
96. Liou JP, Chang CL, Kuo FM, Chang CW, Tseng HY, Wang CC, et al. Concise synthesis and structure-activity relationships of 1-aroylindoles and 3-aroylindoles, combretastatin A-4 analogues, as a novel class of potent antitubulin agents. J Med Chem 2004; 47: 4247-57.
97. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee S J, et al. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 2004; 64: 4621-8.
98. Wu-Wong JR, Alder JD, Alder L, Burns D J, Han EK, Credo B, et al. Identification and characterization of A-105972, an antineo-plastic agent. Cancer Res 2001; 61: 1486-92.
99. Tahir SK, Han EK, Credo B, Jae HS, Pietenpol JA, Scatena CD, et al. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res 2001; 61: 5480-5.
100. Szczepankiewicz BG, Liu G, Jae HS, Tasker AS, Gunawardana IW, von Geldern TW, et al. New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models. J Med Chem 2001; 44: 4416-30.
101. Li Q, Woods KW, Claiborne A, Gwaltney SL 2nd, Barr K J, Liu G, et al. Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent. Bioorg Med Chem Lett 2002; 12: 465-9.
102. Tahir SK, Nukkala MA, Zielinski Mozny NA, Credo RB, Warner RB, Li Q, et al. Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative. Mol Cancer Ther 2003; 2: 227-33.
103. Flynn BL, Verdier-Pinard P, Hamel E. A novel palladium-mediated coupling approach to 2, 3-disubstituted benzo(b)thiophenes and its application to the synthesis of tubulin binding agents. Org Lett 2001; 3: 651-4.
104. Chen Z, Mocharla VP, Farmer JM, Pettit GR, Hamel E, Pinney KG. Preparation of new anti-tubulin ligands through a dual-mode, addition-elimination reaction to a bromo-substituted alpha, beta-unsaturated sulfoxide. J Org Chem 2000; 65:8811-5.
105. Ducki S, Forrest R, Hadfield JA, Kendall A, Lawrence NJ, McGown AT, et al. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg Med Chem Lett 1998; 8: 1051-6.
106. Beutler JA, Hamel E, Vlietinck AJ, Haemers A, Rajan P, Roitman JN, et al. Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem 1998; 41: 2333-8.
107. Lichius JJ, Thoison O, Montagnac A, Pais M, Gueritte-Voegelein F, Sevenet T, et al. Antimitotic and cytotoxic flavonols from Zieridium pseudobtusifolium and Acronychia porteri. J Nat Prod 1994; 57: 1012-6.
108. Shi Q, Chen K, Li L, Chang J J, Autry C, Kozuka M, et al. Antitumor agents, 154. Cytotoxic and antimitotic flavonols from Polanisia dodecandra. J Nat Prod 1995; 58: 475-82.
109. Mahboobi S, Pongratz H, Hufsky H, Hockemeyer J, Frieser M, Lyssenko A, et al. Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. J Med Chem 2001; 44: 4535-53.
110. Beckers T, Reissmann T, Schmidt M, Burger AM, Fiebig HH, Vanhoefer U, et al. 2-Aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. Cancer Res 2002; 62: 3113-9.
111. Lukehart SA. Causes of morbidity and mortality in developed and developing countries. http://courses.washington.edu/pabio550/2003.
112. Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs 2004; 13: 1171-82.
113. Carbonin P, Zuccala G, Marzetti E, Lo Monaco MR. Coronary risk factors in the elderly: their interactions and treatment. Curr Pharm Design 2003; 9(29): 2465-78.
114. Kurowska EM. Nitric oxide therapies in vascular diseases. Curr Pharm Design 2002; 8(3): 155-66.
115. Schlitzer M. Structure based design of benzophenone-based nonthiol farnesyltransferase inhibitors. Curr Pharm Design 2002; 8(19): 1713-22.